Depocyt

Leukemia, Leukemia, Leukemia, Myelocytic, Acute + 8 more
Treatment
1 FDA approval
20 Active Studies for Depocyt

What is Depocyt

CytarabineThe Generic name of this drug
Treatment SummaryCytarabine is a medication used to treat leukemia, a type of cancer that affects white blood cells. It blocks the production of DNA in cancer cells and is effective during the S phase of the cell cycle. Cytarabine also has properties that can help reduce the symptoms of viruses and suppress the immune system.
Cytarabineis the brand name
image of different drug pills on a surface
Depocyt Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cytarabine
Cytarabine
1990
31

Approved as Treatment by the FDA

Cytarabine, otherwise called Cytarabine, is approved by the FDA for 1 uses including Non-Hodgkin's Lymphoma .
Non-Hodgkin's Lymphoma
Used to treat Non-Hodgkin's Lymphoma (NHL) in combination with Carmustine

Effectiveness

How Depocyt Affects PatientsCytarabine is an antineoplastic drug used to treat certain types of leukemia. It works by disguising itself as a building block of DNA, in order to prevent the formation of new cells. Once it is taken in and metabolized, the active form of the drug damages DNA by blocking the creation of new cells and interfering with the repair of existing cells. Cytarabine is most effective when targeting cells in the S phase of the cell cycle.
How Depocyt works in the bodyCytarabine targets rapidly dividing cells, like cancerous ones. It works by damaging the DNA of these cells, making it difficult for them to reproduce. It also stops cells from progressing from the G1 to S-phase of the cell cycle. The exact way it does this is not fully known, but it may interfere with the DNA polymerase process. Cytarabine has also been found in both DNA and RNA.

When to interrupt dosage

The measure of Depocyt is contingent upon the identified condition, including Leptomeningeal Metastases, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. The amount of dosage is contingent upon the technique of application (e.g. Intravenous or Solution - Intrathecal; Intravenous; Subcutaneous) as depicted in the accompanying table.
Condition
Dosage
Administration
Leukemia
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Neoplasm Metastasis
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Non-Hodgkin's Lymphoma
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Newly Diagnosed
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Acute Lymphoblastic Leukemia
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Leukemia, Myelocytic, Acute
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Leukemia
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Leukemia, Myelocytic, Acute
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Acute Myeloid Leukemia
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous
Acute Promyelocytic Leukemia
, 100.0 mg/mL, 20.0 mg/mL, 200.0 mg/mL, 100.0 mg, 500.0 mg, 2000.0 mg, 1000.0 mg, 50.0 mg, 50.0 mg/mL, 10.0 mg/mL, 5.0 mg/mL
Injection - Intrathecal; Intravenous; Subcutaneous, Intrathecal; Intravenous; Subcutaneous, , Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Injection, Powder, for solution, Powder, for solution - Intrathecal; Intravenous; Subcutaneous, Solution, Solution - Intrathecal; Intravenous; Subcutaneous, Liquid, Liquid - Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intrathecal; Intravenous; Subcutaneous, Intrathecal, Injection, suspension, Injection, suspension - Intrathecal, Intravenous, Injection, solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Suspension, Suspension - Intrathecal, Injection, lipid complex - Intrathecal, Injection, lipid complex, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intrathecal; Intravenous; Subcutaneous, Powder, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder - Intravenous

Warnings

There are 20 known major drug interactions with Depocyt.
Common Depocyt Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Cytarabine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Cytarabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Cytarabine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Cytarabine is combined with Acteoside.
Depocyt Toxicity & Overdose RiskOverdosing on cytarabine can cause the "cytarabine syndrome," with symptoms such as fever, muscle pain, bone pain, chest pain, a rash, red eyes, and feeling unwell.
image of a doctor in a lab doing drug, clinical research

Depocyt Novel Uses: Which Conditions Have a Clinical Trial Featuring Depocyt?

621 active studies are currently being conducted to examine the potential of Depocyt for treating Acute Promyelocytic Leukemia, Leptomeningeal Metastases and prophylaxis against Meningeal leukemia.
Condition
Clinical Trials
Trial Phases
Acute Promyelocytic Leukemia
0 Actively Recruiting
Leukemia, Myelocytic, Acute
0 Actively Recruiting
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
0 Actively Recruiting
Newly Diagnosed
3 Actively Recruiting
Phase 3, Phase 1
Leukemia
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Acute Myeloid Leukemia
278 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Acute Lymphoblastic Leukemia
123 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4
Leukemia, Myelocytic, Acute
0 Actively Recruiting
Leukemia
0 Actively Recruiting
Non-Hodgkin's Lymphoma
138 Actively Recruiting
Phase 2, Phase 1, Early Phase 1, Not Applicable, Phase 3

Depocyt Reviews: What are patients saying about Depocyt?

5Patient Review
1/8/2012
Depocyt for Lymphoma Spread to Brain & Spinal Cord Lining
I had ten treatments of Omya reservoir 4Tipotika in my lower spinal column. Afterward, my chronic fatigue syndrome was gone. I used to have migraines too, but they're also gone now. I'm very happy with the results!
5Patient Review
7/17/2008
Depocyt for Lymphoma Spread to Brain & Spinal Cord Lining
After four doses of this treatment, I saw a total eradication of my lymphoma in the central nervous system. Unfortunately, it came back about nine months later. I went through a second round of treatment, this time biweekly for four sessions.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about depocyt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is DepoCyt still available?

"Pacira Pharmaceuticals Inc. has discontinued DepoCyt, a treatment for lymphomatous meningitis, due to manufacturing challenges, the company announced Wednesday."

Answered by AI

What is the use of cytarabine injection?

"Cytarabine is used to treat certain types of leukemia, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML). Cytarabine can be used alone or with other chemotherapy drugs."

Answered by AI

How is cytarabine liposomal administered?

"Liposomal cytarabine is given by intraventricular or intrathecal infusion in order to reach the cerebrospinal fluid surrounding the brain and spinal cord."

Answered by AI

What is cytarabine liposome injection?

"-DepoCyt is indicated for intrathecal treatment of lymphomatous meningitis -DepoCyt is a cytotoxic anticancer drug, handle with caution -Be sure to follow all handling instructions to prepare DepoCyt for administration"

Answered by AI

Clinical Trials for Depocyt

Have you considered Depocyt clinical trials? We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Have you considered Depocyt clinical trials? We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Have you considered Depocyt clinical trials? We made a collection of clinical trials featuring Depocyt, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top